INVESTABOT
Equity Research
XNYS · SERVICES-MEDICAL LABORATORIES
Includes notes from domestic 8-K and foreign private issuer 6-K disclosures.
Quest Diagnostics (DGX) had 1 Form 144 pre-sale notice filed on 2026-09-01. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Quest Diagnostics (DGX) had 1 Form 144 pre-sale notice filed on 2026-08-28. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Quest Diagnostics (DGX) had 1 Form 144 pre-sale notice filed on 2026-07-28. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Quest Diagnostics (DGX) had 1 Form 144 pre-sale notice filed on 2026-06-04. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
Quest Diagnostics (DGX) had 1 Form 144 pre-sale notice filed on 2026-06-01. Form 144 filings signal an insider's intent to sell securities under SEC Rule 144 — they do not confirm a completed transaction. At least one…
open-market Form 4 only - grants, exercises, tax withholding excluded
0 buyers - 3 unique sellers · 6 accumulating - 5 trimming - 1 unchanged
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| September 1, 2026 | Davis J. E. | CEO and President | SELL | -10,000 | $243 | ~$2.4M |
| August 28, 2026 | Prevoznik Michael E | SVP & General Counsel | OPTION_EXERCISE | 22,677 | $112 | ~$2.5M |
| August 28, 2026 | Prevoznik Michael E | SVP & General Counsel | SELL | -16,010 | $243 | ~$3.9M |
| August 28, 2026 | Prevoznik Michael E | SVP & General Counsel | SELL | -6,237 | $244 | ~$1.5M |
| August 28, 2026 | Prevoznik Michael E | SVP & General Counsel | SELL | -430 | $245 | ~$0.1M |
| August 28, 2026 | Prevoznik Michael E | SVP & General Counsel | GIFT | -1,000 | — | — |
| August 28, 2026 | Prevoznik Michael E | SVP & General Counsel | OPTION_EXERCISE | -22,677 | $112 | ~$2.5M |
| July 28, 2026 | Delaney Mark E | SVP & Chief Commercial Officer | SELL | -1,600 | $235 | ~$0.4M |
| July 22, 2026 | Kuppusamy Karthik | SVP, Clinical Solutions | OTHER | 37 | $207 | ~$8K |
| July 22, 2026 | Carter Robert B | — | OTHER | 11 | $207 | ~$2K |
| July 22, 2026 | Gregg Vicky B | — | GRANT | 72 | $207 | ~$15K |
| July 22, 2026 | Plewman Patrick | SVP for Diagnostic Services | OTHER | 46 | $207 | ~$10K |
| July 22, 2026 | Main Timothy L | — | OTHER | 21 | $207 | ~$4K |
| July 22, 2026 | Samad Sam | Executive Vice President & CFO | GRANT | 102 | $207 | ~$21K |
| July 22, 2026 | Lassiter Wright III | — | OTHER | 6 | $207 | ~$1K |
| July 22, 2026 | Delaney Mark E | SVP & Chief Commercial Officer | OTHER | 34 | $207 | ~$7K |
| July 1, 2026 | Wentworth Timothy C | — | GRANT | 144 | — | — |
| June 4, 2026 | Kuppusamy Karthik | SVP, Clinical Solutions | OPTION_EXERCISE | 3,320 | $128 | ~$0.4M |
| June 4, 2026 | Kuppusamy Karthik | SVP, Clinical Solutions | OPTION_EXERCISE | 4,827 | $122 | ~$0.6M |
| June 4, 2026 | Kuppusamy Karthik | SVP, Clinical Solutions | SELL | -8,147 | $200 | ~$1.6M |
| Institution | Shares | Value ($) | Change % | Filing date |
|---|---|---|---|---|
| Vanguard Group | 14,392,082 | ~$2.5B | — | January 29, 2026 |
| BlackRock | 9,275,411 | ~$2.0B | 1.1% | August 7, 2026 |
| BlackRock | 9,172,292 | ~$1.8B | -3.0% | May 13, 2026 |
| BlackRock | 9,459,218 | ~$1.6B | — | February 12, 2026 |
| BlackRock | 10,059,403 | ~$1.4B | — | August 13, 2024 |
| State Street | 5,516,643 | ~$1.2B | 2.5% | August 7, 2026 |
| State Street | 5,380,821 | ~$1.1B | -0.0% | May 15, 2026 |
| State Street | 5,382,547 | ~$934.0M | — | February 13, 2026 |
| JP Morgan Chase | 3,846,456 | ~$758.4M | -7.2% | May 13, 2026 |
| JP Morgan Chase | 3,520,438 | ~$748.6M | -8.5% | August 12, 2026 |
| JP Morgan Chase | 4,145,896 | ~$719.4M | — | February 11, 2026 |
| Morgan Stanley | 2,460,497 | ~$521.5M | -0.8% | August 13, 2026 |
| Morgan Stanley | 2,479,720 | ~$486.0M | -7.9% | May 15, 2026 |
| Morgan Stanley | 2,693,568 | ~$467.4M | — | May 27, 2026 |
| Goldman Sachs | 1,762,925 | ~$305.9M | — | March 25, 2026 |
| Fidelity (FMR) | 1,398,735 | ~$296.5M | 48.5% | August 13, 2026 |
| Goldman Sachs | 1,348,694 | ~$264.3M | -23.5% | May 15, 2026 |
| Fidelity (FMR) | 1,202,254 | ~$208.6M | — | February 17, 2026 |
| Goldman Sachs | 982,694 | ~$208.3M | -27.1% | August 14, 2026 |
| Fidelity (FMR) | 942,218 | ~$184.7M | -21.6% | May 15, 2026 |